EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Agreement between Cerebrospinal Fluid Biomarkers, Brain 18-Fluorodeoxyglucose PET, and Clinical Diagnosis in Older Adults with Cognitive Impairment

Mimenza-Alvarado Alberto J, León-Del-Ángel Karen G, Hernández-Ramírez Rodrigo, Rodríguez-Callejas Juan de D, Yeverino-Castro Sara G, Aguilar-Navarro Sara G

Revista de Investigación Clínica · 2024

DOI: 10.24875/ric.24000161 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Revista de Investigación Clínica, 2024. Verfasst von Mimenza-Alvarado Alberto J und 5 weiteren Autor:innen. Beteiligte Einrichtung: Geriatric Medicine and Neurology Fellowship Program; 2Department of Geriatrics; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirá…. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Biomarkers, Cognitive Dysfunction, Positron-Emission Tomography. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clinical practice has advanced toward a combined diagnostic approach that involves clinical criteria and biological markers for Alzheimer´s disease (AD) and other dementias.

Objective

To establish the level of diagnostic agreement between an initial clinical diagnosis and cerebrospinal fluid (CSF) and [18F]-fluorodeoxyglucose (FDG)-positron emission tomography (PET) biomarkers in a cohort of patients from a memory clinic.

Methods

This is a observational, retrospective, cohort study conducted at an outpatient memory clinic. Between July 2018 and September 2023, data from adults´ ≥ 55 years with a mild cognitive impairment or dementia diagnosis without etiological diagnosis were obtained, complemented with the evaluation of biomarkers in CSF and [18F] FDG-PET biomarker assessment were included. Kappa coefficients (κ) were used to establish the level of agreement between CSF and [18F] FDG-PET results.

Results

Seventy-seven patients had an available [18F] FDG-PET scan, and 25 (32.5%) had both biomarkers. We observed a fair-to-moderate diagnostic agreement between patients´ initial and their final diagnosis in the presence of CSF (κ = 0.233, 95% confidence interval [CI]: −0.099-0.566) and [18F] FDG-PET (κ = 0.451, 95% CI: 0.277-0.625, p < 0.001) results. The Kappa value for diagnostic concordance between [18F] FDG-PET and CSF to differentiate between AD and other dementias was 0.733 (95% CI: 0.425-1.000, p < 0.005).

Conclusion

This study demonstrates good agreement between the CSF and FDG-PET biomarkers to differentiate AD from other dementias. (Rev Invest Clin. 2024;76(5):230-7)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fluorodeoxyglucose F18BiomarkersCognitive DysfunctionPositron-Emission TomographyDementiaAlzheimer DiseaseRadiopharmaceuticalsHumansFemaleMaleAgedRetrospective StudiesMiddle AgedCohort StudiesBrainAged, 80 and over

Stichwörter der Autor:innen

18F-Fluorodeoxyglucose-positron emission tomographyAlzheimer’s diseaseBrain agingCerebrospinal fluidCognitive impairmentDementia

Substanzen

Fluorodeoxyglucose F18BiomarkersRadiopharmaceuticals

Autor:innen und Institutionen

  • Geriatric Medicine and Neurology Fellowship Program; 2Department of Geriatrics; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
  • Geriatric Medicine and Neurology Fellowship Program, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
  • Departament of Nuclear Medicine, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
  • Department of Geriatric, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico;Centro de Investigación sobre el Envejecimiento-CINVESTAV Sede Sur, Mexico City, Mexico.

Zitieren

APA

Alberto J, M. A., Karen G, L. D., Rodrigo, H. R., Juan de D, R. C., Sara G, Y. C., & Sara G, A. N. (2024). Agreement between Cerebrospinal Fluid Biomarkers, Brain 18-Fluorodeoxyglucose PET, and Clinical Diagnosis in Older Adults with Cognitive Impairment. Revista de Investigación Clínica. https://doi.org/10.24875/ric.24000161

Vancouver

Alberto J MA, Karen G LD, Rodrigo HR, Juan de D RC, Sara G YC, Sara G AN. Agreement between Cerebrospinal Fluid Biomarkers, Brain 18-Fluorodeoxyglucose PET, and Clinical Diagnosis in Older Adults with Cognitive Impairment. Revista de Investigación Clínica. 2024. doi:10.24875/ric.24000161

BibTeX
@article{AlbertoJ2024,
  author = {Alberto J, Mimenza-Alvarado and Karen G, León-Del-Ángel and Rodrigo, Hernández-Ramírez and Juan de D, Rodríguez-Callejas and Sara G, Yeverino-Castro and Sara G, Aguilar-Navarro},
  title = {Agreement between Cerebrospinal Fluid Biomarkers, Brain 18-Fluorodeoxyglucose PET, and Clinical Diagnosis in Older Adults with Cognitive Impairment},
  journal = {Revista de Investigación Clínica},
  year = {2024},
  doi = {10.24875/ric.24000161}
}
Kostenlos starten →